Avramis V I
University of Southern California, School of Medicine, Department of Pediatrics.
Cancer Invest. 1989;7(2):129-37. doi: 10.3109/07357908909038280.
The cellular metabolism of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'monophosphate (F-araAMP), a soluble nucleoside analog with proven antileukemic activity in animal and human tumors, has been studied in mice bearing P388 leukemia. Earlier studies showed markedly less in vivo accumulation of F-ara ATP the principal active metabolite, in gastrointestinal mucosa (GI) and bone marrow (BM) compared with P388 after F-araA or F-araAMP administration. To elucidate the mechanism of toxicity this work has examined the pharmacodynamics of F-araAMP anabolites, F-araATP and F-ATP, in P388 cells, BM and GI mucosa tissues after nontoxic (LD1) and toxic (LD50) doses of F-araAMP. F-araATP was the major triphosphate metabolite in acid-soluble extracts from P388 cells, BM, and GI mucosa tissues. F-araATP accumulated to approximately 1 mM in P388 cells after either LD1 or LD50 treatment of F-araAMP and was eliminated with a t1/2,el of approximately 5 h. The ratio of the area under the concentration-time curve (AUC 0----infinity) of F-araATP was 1.01 after the LD50 over the LD1 doses of F-araAMP. BM and GI mucosa tissues accumulated 40-fold less F-araATP than the concentration in P388 cells. 2-Fluoro-ATP, a second toxic anabolite, accumulated in P388 cells to 156 +/- 39 microM and 447 +/- 79 microM after the two doses of the drug, respectively. The ratio of area under the curve (AUC) of F-ATP in P388 cells after the two doses of F-araAMP was 38.77, which approaches the ratio of % lethality (LD50/LD1 = 50). F-ATP was also quantitated in BM and GI mucosa reaching one-fifth to one-half the concentration of F-araATP after the LD50 dose of F-araAMP. The AUC values of F-ATP (0----24 h) were 9.5- to 12.5-fold higher after the LD50 than after the LD1 dose of F-araAMP. These results suggest that there is a selective therapeutic action of F-araAMP against P388 and that the increased cellular concentration of F-ATP in both the tumor cells and the host tissues (BM and GI mucosa) could explain the mode of toxicity of F-araAMP.
9-β-D-阿拉伯呋喃糖基-2-氟腺嘌呤5'-单磷酸酯(F-araAMP)是一种可溶性核苷类似物,在动物和人类肿瘤中已证实具有抗白血病活性。本文对荷P388白血病小鼠体内该物质的细胞代谢进行了研究。早期研究表明,给予F-araA或F-araAMP后,与P388细胞相比,胃肠道黏膜(GI)和骨髓(BM)中主要活性代谢产物F-ara ATP的体内蓄积明显较少。为阐明毒性机制,本研究检测了无毒(LD1)和有毒(LD50)剂量的F-araAMP作用后,P388细胞、BM和GI黏膜组织中F-araAMP合成代谢产物F-araATP和F-ATP的药效学。F-araATP是P388细胞、BM和GI黏膜组织酸溶性提取物中的主要三磷酸代谢产物。给予LD1或LD50剂量的F-araAMP后,P388细胞中F-araATP蓄积至约1 mM,并以约5小时的消除半衰期(t1/2,el)消除。F-araAMP的LD50剂量与LD1剂量相比,F-araATP浓度-时间曲线下面积(AUC 0至无穷大)的比值为1.01。BM和GI黏膜组织中F-araATP的蓄积量比P388细胞中的浓度低40倍。第二种有毒合成代谢产物2-氟-ATP在给予两剂药物后,在P388细胞中分别蓄积至156±39 μM和447±79 μM。给予两剂F-araAMP后,P388细胞中F-ATP的曲线下面积(AUC)比值为38.77,接近致死率比值(LD50/LD1 = 50)。在BM和GI黏膜中也对F-ATP进行了定量,给予LD50剂量的F-araAMP后,其浓度达到F-araATP浓度的五分之一至二分之一。F-araAMP的LD50剂量与LD1剂量相比,F-ATP的AUC值(0至24小时)高9.5至12.5倍。这些结果表明,F-araAMP对P388具有选择性治疗作用,肿瘤细胞和宿主组织(BM和GI黏膜)中F-ATP细胞浓度的增加可以解释F-araAMP的毒性模式。